Sarepta Therapeutics, Inc. (SRPT)
NEUTRALFundamental
44
मूल्य
$18.55
मार्केट कैप
$1.92B
भाग 1 · कंपनी का मूल्य कितना है
अवलोकन
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an AAV-based gene therapy, which is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the Duchenne gene. The company also develops SRP-9003, a gene therapy program for the treatment of LGMD2E; SRP-1001 to selectively target and knockdown DUX4 using RNAi in Phase 1/2a clinical trials; and SRP-1003 for reduction of expression of the DMPK gene in Phase 1/2a clinical trials. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Arrowhead Pharmaceuticals, Inc.; University of Western Australia; Nationwide Children's Hospital; Hansa Biopharma; and Duke University. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
बैलेंस शीट और तरलता
राजस्व
$1.47B
पिछले 12 महीने (30/6/2026 तक)
शुद्ध आय
$-137M
पिछले 12 महीने (30/6/2026 तक)
Free Cash Flow
$-307M
कुल इक्विटी
$1.14B
कुल देनदारियाँ
$2.21B
Current Ratio
4.42
Interest Coverage
18.35
Debt/EBITDA
-
Earnings Per Share
राजस्व और शुद्ध आय
Free Cash Flow
आय विवरण
ऐतिहासिक विवरण
समय के साथ मार्जिन
समय के साथ ऋण
ऋण कितना भारी है
वृद्धि तालिका
वृद्धि — राजस्व
Fair Value अनुमान
Fair Value
$14.99
वर्तमान मूल्य
$18.55
Margin of Safety
-23.7%
Fair Value सीमा
$9.75 - $20.24
अनुमान विधियाँ
मूल्यांकन मेट्रिक्स
P/E Ratio
-
ROE
-62.5%
P/B Ratio
1.25
P/FCF
23.40
Gross Margin
98.6%
ROIC
-24.5%
लाभप्रदता Radar
Value Creation (Economic Moat)
ROIC
-24.5%
WACC
6.2%
ROIC − WACC
-30.7 pp
ROIC is below the cost of capital — the company is destroying value for every dollar invested.
Fundamental विश्लेषण मानदंड
पास (10)
- Gross Margin 98.6%
- P/FCF 23.40
- P/B Ratio 1.25
- Debt/Equity ratio
- Positive Free Cash Flow
- Current Ratio
- Interest Coverage
- Low reliance on intangibles
- Revenue Growth 5Y 32.4%
- Share Dilution -0.5%
फेल (12)
- EPS shows upward trend
- Price CAGR -3.71%
- ROIC -24.5%
- Operating Margin -37.5%
- CapEx intensity
- Return on Tangible Assets
- DCF valuation (Overvalued)
- ROE -10.0%
- Analyst Consensus 42% Buy
- Earnings Surprise avg -12.2%
- Net Margin Trend -9.3% vs -2.6%
- Piotroski F-Score 3/9
अनुपलब्ध (5)
- Dividend Payout NaN%
- Debt/EBITDA
- Price below Graham Number
- PEG Ratio (need PE > 0 and growth > 0)
- Earnings Quality (OCF/Net Income)
Piotroski F-Score
गंभीर वित्तीय चिंताएं
Earnings गुणवत्ता
निम्न गुणवत्ता: accounting की जांच करें
शेयर Dilution
शेयर वापस खरीद रही है। शेयरधारक अनुकूल
प्रशासन
कार्यकारी टीम
| नाम | पद | आयु |
|---|---|---|
| Mr. Ian Michael Estepan | President & COO | 49 |
| Mr. Ryan H. Wong | Executive VP & CFO | 46 |
| Ms. Cristin L. Rothfuss J.D. | Executive VP, General Counsel & Company Secretary | 57 |
| Mr. Douglas S. Ingram Esq., J.D. | Advisor | 62 |
| Dr. Louise R. Rodino-Klapac Ph.D. | President of Research & Development and Technical Operations | 47 |
| Dr. Michael E. Severino M.D. | CEO & Director | 59 |
| Rachael Potter Ph.D. | Chief Scientific Officer | - |
| Tamara Thornton | Director of Finance, Treasury & Investor Relations | - |
| Ms. Alison Nasisi | Executive VP & Chief People Officer | - |
| Dr. Diane L. Berry Ph.D. | Executive VP and Chief of Global Policy & Advocacy Officer | - |
Audit जोखिम
7
बोर्ड जोखिम
2
मुआवजा जोखिम
10
शेयरधारक अधिकार जोखिम
3
भाग 2 · कीमत और खरीदने का समय
यह हिस्सा यह नहीं बताता कि कंपनी अच्छी है या नहीं: यह तय करने में मदद करता है कि उसे कब खरीदें, जब फंडामेंटल आपको आश्वस्त कर चुके हों। इसमें: तकनीकी विश्लेषण, संभावना, ऐतिहासिक गिरावट, गामा एक्सपोज़र।
Latest News
Recent headlines for SRPT, sourced from Markets Gazette.
- 3/19/2026NEGATIVESarepta To Request FDA For Traditional Approvals For Duchenne Drugs
Sarepta Therapeutics Inc. (SRPT) shares experienced a decline following an update from the U.S. Food and Drug Administration (FDA) and mixed clinical trial results for its Duchenne muscular dystrophy drugs. While the company intends to seek traditional approvals, the market is currently weighing the potential for regulatory success against the less-than-convincing trial data. This uncertainty introduces significant risk for investors, as the path to full approval appears more challenging than initially anticipated, potentially impacting future revenue streams and market valuation.
- 2/25/2026NEUTRALSarepta (SRPT) Q4 2025 Earnings Call Transcript
The market awaits crucial details regarding Sarepta Therapeutics' (SRPT) Q4 2025 earnings call transcript. While the event was scheduled, specific information on financial results, future projections, and updates on key products has not yet been made public. Investors will closely monitor the release of this data to assess the company's performance during the period and its growth prospects, particularly concerning advancements in neuromuscular disease treatments. The immediate lack of details maintains a climate of uncertainty, with the stock potentially reacting significantly once the information becomes available and is analyzed by market participants.
via Markets Gazette